Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1Lymphoid 1CNS 1

Conditions

Lymphoma, Large-Cell, Anaplastic 4Granuloma, Plasma Cell 3Hematologic Neoplasms 2Rhabdomyosarcoma 1Neuroblastoma 1Neoplasms 1Lymphoma, B-Cell 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

X-Rays 5Phantoms, Imaging 5Magnetic Resonance Spectroscopy 5Specimen Handling 4Nuclear Medicine Department, Hospital 4Biopsy 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2palbociclib 2olaparib 2larotrectinib 2ivosidenib 2ensartinib 2Vemurafenib 2Stem Cell Transplantation 2Nivolumab 2LY3023414 2thymoglobulin 1surufatinib 1fludarabine 1erdafitinib 1dostarlimab 1copanlisib 1ceritinib 1bempegaldesleukin 1amino-acid, glucose, and electrolyte solution 1Zoledronic Acid 1Sirolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rhabdomyosarcoma × ceritinib × Lymphoid × Clear all
NCT01742286 2020-06-09

Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)

Novartis

Phase 1 Completed
83 enrolled 30 charts
CNSLymphoidPlasma cellSarcoma

Granuloma, Plasma Cell, Neoplasms, Neuroblastoma, Rhabdomyosarcoma, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡